International effort to improve prognostication in NDMM patients: R2-ISS. Intermediate risk patients can be divided in 2 groups, 1q+ should be included in the risk calculation, the coexistence of several risk factors should be taken into account. https://t.co/K7Qvsmr441
Delegation of young hematologist from Torino at post ASH meeting in Genova, Italy.
It's good to return to live meetings after so many months.
#postash#hematology#younghematologists
So proud of being part of this important step forward to the best treatment of #myeloma . FORTE trial is out! Thanks to my mentors prof Boccadoro and Gay for the big opportunity
https://t.co/C8P7Zu6lWL